The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits
about
New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channelsCharacterization of KCNQ5/Q3 potassium channels expressed in mammalian cellsDiverse mechanisms of antiepileptic drugs in the development pipelineMolecular targets for antiepileptic drug developmentRetigabine: has the orphan found a home?New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapyM-current preservation contributes to anticonvulsant effects of valproic acid.Homeostasis or channelopathy? Acquired cell type-specific ion channel changes in temporal lobe epilepsy and their antiepileptic potentialIon channels and epilepsyRetigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 MutationsAKAP150 signaling complex promotes suppression of the M-current by muscarinic agonistsRescue of homeostatic regulation of striatal excitability and locomotor activity in a mouse model of Huntington's disease.Is there a role for potassium channel openers in neuronal ion channel disorders?Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy.Peripheral channelopathies as targets for potassium channel openers.Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.Emerging drugs for epilepsy.Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizuresNanotechnology for neuronal ion channels.Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker.Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders.Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystoniaClinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.Refractory epilepsy: mechanisms and solutions.One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.Retigabine holds KV7 channels open and stabilizes the resting potential.The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential.Retigabine.Emerging drugs for partial-onset epilepsy: a review of brivaracetamAntiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.Inside job: ligand-receptor pharmacology beneath the plasma membrane.Somatostatin: an endogenous antiepilepticNervous system KV7 disorders: breakdown of a subthreshold brake.Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencingSeizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10.K+ channel modulators for the treatment of neurological disorders and autoimmune diseasesEfficacy of retigabine in adjunctive treatment of partial onset seizures in adults.
P2860
Q24654230-B4A3B395-40F5-4E21-9AC9-8E0480029809Q24674102-BFB2A7B2-0EDE-4AD9-B42A-9DF0286B1076Q24675330-73ECB943-A156-4959-BE1A-ACE32ABAA561Q24683346-E8516061-A1C9-4AC2-BBAA-BAF8799AF040Q24685444-1296C727-1C56-4A43-A5E2-727AD7D9CA4FQ27007942-3653DC13-2943-4331-B5ED-BF514DA6C3C1Q27332374-B46CBF24-AFFD-4FC2-9495-86680039F832Q28080655-CB8F35AC-A1EE-4B68-B2DE-38EC9BADEA6FQ28189601-76ADA965-A215-4F9B-9FB4-5979F03B02C2Q28550367-E860B017-FD56-43BA-8594-F719849CC88BQ28574598-3F6FF062-6549-4DD6-9F71-48DCADE2BB32Q30622772-F58F5610-CBB7-4AB8-B326-D4BCB0901CD4Q34075106-312E1F6F-CC59-49B8-85F5-BF7F028BD648Q34114419-66E9E21F-BFA6-4BBE-A3FB-A8B4102FEAD8Q34333196-A9E56B6E-CCB1-4C1D-A356-3C7B106A82A1Q34393213-3BEB0AD5-0D43-47B1-B62A-37640BDBC85AQ34481593-72B9BD03-DE61-43F1-B243-F3037C7B8B88Q34558128-1DB83E32-8026-4D89-9148-77D0572C080AQ34688725-29BE1B88-A127-4F32-BD46-2EEBA39C839DQ35117817-DAB368D9-35E7-4955-8C47-9F2E30E61505Q35583803-4275025D-0E09-4FAA-BA42-7396CD268980Q35683922-644A5369-1534-4272-AB6A-E414628C3709Q35872543-9F6DBE0A-54CC-4D95-B5B6-FE049387A488Q35911129-6F7B0FC6-317B-409D-88DE-7BBA04817AE6Q36054393-F9ABF5F5-C40B-43B7-B054-6B8A56C7209EQ36144410-21F866BE-E5B5-4DF2-8F27-AF76335A25B9Q36419584-66790A6D-47A5-4C5B-B08F-D1531AC694E0Q36603168-1CDC403D-C2D6-4489-8914-DDDD379C8DB2Q36634324-EA35961B-E2D1-4D3F-AB53-54E15A0075CBQ36675813-E28B84D0-CDE7-4507-8D46-810E4B01735BQ36697501-DFA7C2B6-B199-4288-A9A7-77765F15C34FQ36891212-3C2CC323-AF13-4B86-A80B-A20A0CE3C081Q36958975-A6A22820-E332-444A-B763-9664D344C0C6Q36989788-BDA68CF7-4116-42AD-BC8A-F49944693B51Q37067748-A5A737F7-5EAA-4CDB-9FD3-C8DE83311171Q37073177-1F70EF89-35B6-4E65-B828-C376278BDE10Q37083418-64424C3F-612C-4F10-BFB5-454A5C6888E0Q37130485-17589809-2AE7-4F55-85A8-ECAD5AD1E208Q37162392-58194457-7829-42ED-BF6B-BDB9AACF16AFQ37302567-1906B397-E919-41B6-8740-45DBCB26D791
P2860
The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@ast
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@en
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@nl
type
label
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@ast
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@en
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@nl
prefLabel
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@ast
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@en
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@nl
P3181
P1433
P1476
The novel anticonvulsant retig ...... ed with human KCNQ2/3 subunits
@en
P2093
P3181
P356
10.1016/S0304-3940(00)00866-1
P407
P577
2000-03-17T00:00:00Z